USP22 and cholangiocarcinoma: The underpinning protumourigenic USP22 on tumour cells was EMT induction, exhibiting loss of epithelial E-cadherin and gain of mesenchymal vimentin, with upregulation of MMP2/9 invasive markers in CCA cell lines.